Cochrane · systematic review · CD004678
Glatiramer acetate for multiple sclerosis
La Mantia, L, Munari, LM, Lovati, R · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
0
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 6 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Glatiramer acetate versus placebo in relapsing remitting patient for multiple sclerosis
Population: patients with multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patients who progressed ‐ at 2 years Glatiramer acetate vs placebo | RR 0.75 [0.51, 1.12] | 2 studies · 299 participants | Ungraded |
Patients who progressed ‐ at 35 months Glatiramer acetate vs placebo | RR 0.81 [0.5, 1.29] | 1 study · 203 participants | Ungraded |
Change in disability score at the end of Glatiramer acetate vs placebo | no estimate extracted | 2 studies · 301 participants | Ungraded |
Change in disability score at the end of Glatiramer acetate vs placebo | no estimate extracted | 1 study · 203 participants | Ungraded |
Mean number of relapses ‐ within 1 year of Glatiramer acetate vs placebo | no estimate extracted | 2 studies · 287 participants | Ungraded |
Mean number of relapses ‐ at 2 years of Glatiramer acetate vs placebo | no estimate extracted | 2 studies · 298 participants | Ungraded |